RxDoctor Payments Data

Krishna Thavarajah, MD

Pulmonary Disease · Detroit, MINPI 1598989329

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $5,997 of the $6,863 with a category attached, or 87.4%. Boehringer Ingelheim accounts for 68.7% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2024 at $4,160 and has fallen 93.2% since, to $284 in 2025.

$6,863in general payments, 2019–2025

Across 10 payments — averaging $686.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$5K
  • Genentech USA, Inc.$2K
$150,171in research payments, 2019–2025

Across 87 payments — averaging $1726.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • United Therapeutics Corporation$109K
  • Boehringer Ingelheim$37K
  • Boehringer Ingelheim International GmbH$2K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$1K
  • Boehringer Ingelheim Limited$766

What the payments were for

  • Speaking & faculty fees$5,99787%
  • Food & beverage$86713%

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boehringer Ingelheim8$4,712
Genentech USA, Inc.2$2,151

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,863 in reported general payments places this provider in the 75th percentile of 463 pulmonary disease providers in Michigan.

See all pulmonary disease providers in Michigan

Medicare billing

Part B allowed, 2024
$32,457
Medicare patients
141
Services billed
357

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate115$1,409,834
Pirfenidone127$211,433
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$38,535
Spiriva RespimatTiotropium Bromide17$14,402
Mycophenolic AcidMycophenolate Sodium53$9,106
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$5,875
Mycophenolate Mofetil29$4,476
Breo ElliptaFluticasone/Vilanterol12$4,187
Fluticasone-SalmeterolFluticasone Propion/Salmeterol23$3,690
Albuterol Sulfate HfaAlbuterol Sulfate74$3,670
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate11$2,768
Famotidine93$1,199
Azathioprine23$766
Prednisone88$734
Fluticasone Propionate37$621

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat$4,712$1,424,237132 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 463 pulmonary disease providers in Michigan.

Other pulmonary disease in Detroit

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →